# Kerala govt defends generic SMA drug, will cut price further 2026-10-26T10:15:41+00:00 | Governance | Indian Opinion Desk Corroboration: 2 independent outlets The Congress-led UDF government in Keralam on Monday strongly defended switching to a generic drug for spinal muscular atrophy (SMA) patients, saying it would try to reduce the price further. Health Minister K Muraleedharan told the Assembly the government eventually aimed to offer medicines free to all SMA patients, and an announcement would be made in due course. Chief Minister V D Satheesan said the generic alternative, marketed by Natco Pharma, cost Rs 15,000 compared with Rs 6.5 lakh for branded Risdiplam for 12 days. The drug had court orders and statutory clearances, he said, adding the price could be lowered to Rs 9,000. The CPI(M)-led Opposition LDF moved an adjournment motion alleging ‘clinical trials’ on patients and a corporatisation agenda through a new task force. Leader of Opposition Pinarayi Vijayan said the government was misleading the House, and targeted the inclusion of former Uttar Pradesh Chief Secretary Deepak Singhal in the task force, citing his links to Global Trade and Technology Council India. The motion was rejected, and the Opposition walked out. ## Indian Opinion Analysis The government-critical framing by Onmanorama leads with the task force controversy and presents the Opposition's charges at length, Singhal's corruption allegations, GTTCI links, and the CM reading out names as “his defence”, while relegating the SMA drug price cuts to context. The Hindu leads with the price reduction announcement and the Health Minister's promise of free medicines, giving the CM's defence equal weight and naming Opposition charges only in later paragraphs. That both outlets report the same walkout and rejected motion confirms the headline event, the difference lies in which detail is foregrounded. The balance: the UDF side has concrete numbers (Rs 15,000, scope for Rs 9,000) and cleared vigilance charges, while the LDF side has no counter-figures but questions a specific appointment the government must answer, with the Assembly adjourned after the walkout. ## Coverage Coverage: 2 sources, 1 government-critical, 1 neutral - onmanorama.com (government critical) Leads with task force, frames CM's name list as defensive, features Opposition charges prominently - thehindu.com (neutral report) Leads with price cut and free medicine promise, gives government defense first This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Tags: Deepak Singhal, Kerala Legislative Assembly, Natco Pharma, Pinarayi Vijayan, spinal muscular atrophy, V.D. Satheesan Canonical: https://indianopinion.org/kerala-govt-defends-generic-sma-drug-will-cut-price-further/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/kerala-govt-defends-generic-sma-drug-will-cut-price-further/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/